Bluebird bio’s future in balance as FDA weighs gene therapy approvals

Two gene therapies it’s developed are under review by the Food and Drug Administration and, if approved, would become only the third and fourth cleared by the agency for use in treating inherited diseases.

But Bluebird, a pioneer in the field, simultaneously faces financial peril. The Massachusetts-based biotech is quickly running out of cash and earlier this year warned investors that it may struggle to stay solvent. It’s already cutting costs.